korrents

korrents · piece

Metformin and cancer: active surveillance needed

Peter Attia · 4 Jul 2026

Read the piece on peterattiamd.com ↗

3 korrents from this piece ↓

Peter Attia did not write this page.

Every claim below was made in this piece, quoted word for word and numbered in the order the piece makes them, so you can read it there rather than take our word for it. The sentence above each quote is our reading of the claim, not their wording. Each quote was checked against a stored copy of the page at build time; where the two differ, the quote is the fact.

  1. MAST adds to a growing body of evidence suggesting that metformin is not a general-purpose anticancer drug.
  2. we now have multiple trials confirming that metformin interferes with your ability to reap the adaptive benefits of exercise, which is the most powerful broad-based longevity intervention available to us today
  3. That’s a lesson we could all learn about our approach to supplements and even drugs: not to fall for hazy promises that a single molecule will deliver vaguely-defined benefits for all aging persons, but to demand rigorous evidence for well-defined benefits for well-defined problems in well-defined populations.

Keep reading

The other pieces are the ones whose claims are worded most like this one's. That measures language, not agreement: they may argue the opposite.